Dual antiplatelet therapy (DAPT) — use of aspirin with a P2Y12 inhibitor such as clopidogrel, prasugrel, or ticagrelor — is commonly used after vascular events or procedures in patients with coronary artery disease. The duration of therapy is the subject of a new guideline from the American Heart Association and the American College of Cardiology. The guideline recommends a minimal therapy duration of 6-12 months, while therapy beyond 12 months should be reserved for patients at the highest risk of a vascular event. Low-dose aspirin generally should be continued indefinitely in all coronary artery disease patients. The full guideline was published online in the March 29 issue of Circulation.
The guideline recommends a minimal therapy duration of 6-12 months, while therapy beyond 12 months should be reserved for patients at the highest risk of a vascular event.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content